title: Use of tetrahydraindazolone dicarboxylic acid (HIDA) to improve the therapeutic effect in vivo of combined cisplatin, heat and radiation treatment.
abstract: The effect of tetrahydraindazolone dicarboxylic acid (HIDA) on tumour response and mouse lethality after treatment with cisplatin given either alone or combined with hyperthermia (43.5 degrees C/60 min) with or without radiation, was studied in the CDF1 mouse bearing a foot transplanted C3H mouse mammary carcinoma. The tumour response to a combined heat, cisplatin and HIDA treatment was assessed by tumour growth time, while local tumour control was used when irradiation was added to that treatment scheme. Toxicity was estimated as lethality within 14 days. Cisplatin and heat exerted the highest antitumour effect when given simultaneously, but at the same time there was a substantial increase in lethality. No sensitization of the tumour response or enhanced toxicity to cisplatin was observed if heat was given sequentially (i.e. 4 h) after cisplatin. The effect of this sequential schedule being only additive. When HIDA (100 mg/kg) was given 150 min before cisplatin and tumours heated 15 min later, the lethal toxicity was significantly reduced. HIDA did not, however, influence tumour growth time results. In tumour control studies combining radiation, drug and heat, cisplatin (6 mg/kg) and heat (43.5 degrees C/60 min) were given simultaneously 4 h after local irradiating the leg of tumour-bearing mice. The lethality of this regime was more than 55%, but when HIDA was added to the protocol, the toxicity fell to 5% without affecting local tumour control. In conclusion, HIDA administered before cisplatin protects against drug-induced toxicity without reducing the drug's antitumour activity when used alone or in combination with hyperthermia and/or radiation, and thus results in a significantly improved therapeutic benefit.
authors.affiliation: Danish Cancer Society, Department of Experimental Clinical Oncology, Aarhus University Hospital.
authors.forename: J
authors.initials: J
authors.lastname: Overgaard
authors.forename: M
authors.initials: M
authors.lastname: Radacic
authors.forename: D
authors.initials: D
authors.lastname: Skaric
authors.forename: V
authors.initials: V
authors.lastname: Skaric
authors.forename: M R
authors.initials: MR
authors.lastname: Horsman
authors.forename: J C
authors.initials: JC
authors.lastname: Lindegaard
authors.forename: J
authors.initials: J
authors.lastname: Jercic
mesh_terms: D000818:Animals; D002945:Cisplatin / Q000008:administration & dosage* / Q000037:antagonists & inhibitors / Q000633:toxicity; D003131:Combined Modality Therapy; D005069:Evaluation Studies as Topic; D005260:Female; D006979:Hyperthermia, Induced; D007191:Indazoles / Q000008:administration & dosage*; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D051379:Mice; D008809:Mice, Inbred C3H; D008811:Mice, Inbred DBA
chemical_list: D007191:Indazoles; C051797:4,5,6,7-tetrahydro-3-oxo-2H-indazole-5,5-dicarboxylic acid; D002945:Cisplatin